CN112326639B - Kit and method for detecting fructosamine - Google Patents
Kit and method for detecting fructosamine Download PDFInfo
- Publication number
- CN112326639B CN112326639B CN202011345976.4A CN202011345976A CN112326639B CN 112326639 B CN112326639 B CN 112326639B CN 202011345976 A CN202011345976 A CN 202011345976A CN 112326639 B CN112326639 B CN 112326639B
- Authority
- CN
- China
- Prior art keywords
- reagent
- anionic surfactant
- phosphate
- fructosamine
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 33
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 123
- 238000001514 detection method Methods 0.000 claims abstract description 49
- 239000003945 anionic surfactant Substances 0.000 claims abstract description 44
- 210000002966 serum Anatomy 0.000 claims abstract description 31
- FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 claims abstract description 27
- 239000000872 buffer Substances 0.000 claims abstract description 26
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 21
- 239000010452 phosphate Substances 0.000 claims abstract description 21
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 19
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims abstract description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
- 238000002835 absorbance Methods 0.000 claims description 15
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 13
- 229960002897 heparin Drugs 0.000 claims description 13
- 229920000669 heparin Polymers 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 9
- -1 phenolic ether phosphate salt Chemical class 0.000 claims description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 7
- TVACALAUIQMRDF-UHFFFAOYSA-N dodecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCOP(O)(O)=O TVACALAUIQMRDF-UHFFFAOYSA-N 0.000 claims description 5
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical group OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 3
- YVIGPQSYEAOLAD-UHFFFAOYSA-L disodium;dodecyl phosphate Chemical group [Na+].[Na+].CCCCCCCCCCCCOP([O-])([O-])=O YVIGPQSYEAOLAD-UHFFFAOYSA-L 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims 5
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 239000008213 purified water Substances 0.000 description 23
- 239000002904 solvent Substances 0.000 description 22
- 239000004094 surface-active agent Substances 0.000 description 18
- 239000007788 liquid Substances 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 12
- 239000008363 phosphate buffer Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 8
- 239000002736 nonionic surfactant Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000000691 measurement method Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical class [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Chemical group CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 125000005228 aryl sulfonate group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- WCGGWVOVFQNRRS-UHFFFAOYSA-N dichloroacetamide Chemical compound NC(=O)C(Cl)Cl WCGGWVOVFQNRRS-UHFFFAOYSA-N 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- LRMHFDNWKCSEQU-UHFFFAOYSA-N ethoxyethane;phenol Chemical compound CCOCC.OC1=CC=CC=C1 LRMHFDNWKCSEQU-UHFFFAOYSA-N 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940051841 polyoxyethylene ether Drugs 0.000 description 2
- 229920000056 polyoxyethylene ether Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940104261 taurate Drugs 0.000 description 2
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002888 zwitterionic surfactant Substances 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical group [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 108700004049 glycosylated serum Proteins 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- CAVXVRQDZKMZDB-UHFFFAOYSA-M sodium;2-[dodecanoyl(methyl)amino]ethanesulfonate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CCS([O-])(=O)=O CAVXVRQDZKMZDB-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002256 xylenyl group Chemical class C1(C(C=CC=C1)C)(C)* 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
Abstract
The present invention relates to a kit for detecting fructosamine, comprising: a first reagent comprising a carbonate buffer; a second reagent comprising nitrotetrazolium blue and an anionic surfactant; and a calibrator, wherein said anionic surfactant is selected from one or more of phosphate-based anionic surfactants and sulfonate-based anionic surfactants, optionally said kit is for detecting fructosamine in plasma. The invention improves the consistency of the detection results of serum and plasma samples during fructosamine detection. The invention also relates to a method for detecting fructosamine and application of the anionic surfactant in improving consistency of fructosamine detection results.
Description
Technical Field
The invention relates to the field of fructosamine detection, in particular to fructosamine detection based on a nitrotetrazolium blue method.
Background
Fructosamine (FMN) is a derivative produced by non-enzymatic saccharification of glucose with albumin and other protein molecules at the N-terminal amino group in blood, and because of its short half-life (19 d) of glycosylated Albumin (ALB) in blood, it can be used to reflect the average level of blood glucose within the last 2-3 weeks of the body, where the concentration level is positively correlated with blood glucose level. Because FMN has the advantages of convenience in laboratory detection, low cost, insusceptibility to diet and medicines, and the like, the FMN can be combined with other clinical indexes, such as auxiliary judgment for occurrence, progress and prognosis of diabetes.
Fructosamine determination is carried out as follows: affinity chromatography, phenylhydrazine method, fructose method, aldol method, nitrotetrazolium Blue (NBT) method, and ketoamine oxidase method. Among them, ketoamine oxidase method is a newly developed detection method in the United kingdom, and the enzyme method for detecting the concentration of glycosylated serum protein has the advantages of high specificity, good precision, strong anti-interference capability, wide linear range and the like, and is a very promising detection method for glycosylated albumin. But at present, the use and popularization are limited due to higher cost. Relatively speaking, the NBT method is simple and convenient to operate and easy to popularize, and the reagent on the market is mainly the NBT method at present.
Currently, the reagent kit of the commercial NBT method and the 4 th edition of national clinical test operation procedure show that serum samples are required to be used for detecting fructosamine by using the NBT method, and meanwhile, the given reference intervals are the reference intervals of the serum samples; this is because, since there is a certain difference between the components in plasma and serum, the NBT method has a defect that the difference is too large when detecting a plasma sample. For example, yan Cuie et al illustrate the difference between plasma and serum measurements, so many reagent manufacturers produce reagents that are limited to measuring serum samples, which limits the range of reagent use.
Therefore, in the field of fructosamine detection, there is a strong need to expand the variety of samples to be tested and to improve the consistency of the results of serum and plasma detection.
Disclosure of Invention
Throughout the specification, unless specifically indicated otherwise, the terms used herein should be understood as meaning as commonly used in the art. Accordingly, unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present specification will control.
As used hereinafter, the terms "having," "including," or "comprising" are used in a non-exclusive manner. Thus, these terms may refer both to instances in which no additional feature is present in the entity described in this context other than the feature introduced by the terms, and to instances in which one or more additional features are present. As an example, the expressions "a has B", "a contains B" and "a includes B" may refer both to the case where no further elements are present in a except B (i.e. the case where it consists solely and only of B), and to the case where one or more further elements such as elements C, C and D or even other elements are present in entity a except B.
The term "about" in the context of a particular value or ratio of the present invention means +/-10% of the value or ratio, or in one embodiment +/-5% of the given value or ratio.
As described above, the detection of fructosamine is currently generally performed by the nitrotetrazolium blue method, which is based on the following principle: fructosamine in serum can reduce nitrotetrazolium blue to formazan under alkaline conditions. Since there is a large deviation in the detection result in the case of detecting a plasma sample, since the detection object of the method is limited to only a serum sample, this greatly limits the application range of the method.
In order to solve the above problems, the present inventors studied the components of fructosamine detection reagent and found that the consistency of the detection results of serum and plasma samples can be improved when phosphate and/or sulfonate type anionic surfactants are added, thereby completing the present invention.
Accordingly, in one aspect, the present invention provides a kit for detecting fructosamine, comprising:
a first reagent comprising a carbonate buffer;
a second reagent comprising nitrotetrazolium blue and an anionic surfactant; and
the calibration material is used for the calibration of the device,
wherein the anionic surfactant is selected from one or more of phosphate anionic surfactants and sulfonate anionic surfactants.
The terms "first" and "second" and the like in this disclosure are used merely to distinguish between a plurality of similar elements and are not intended to represent any difference in importance or order between the elements.
In some embodiments, the kits of the invention are used to detect fructosamine in plasma.
As used herein, "anionic surfactant" refers to a partially negatively charged surfactant that functions as a surfactant after ionization in water. Structurally, anionic surfactants can be divided into four classes of carboxylate, sulfonate, sulfate, and phosphate.
As used herein, "phosphate type surfactants" may be used interchangeably with "phosphate type anionic surfactants"; the "sulfonate-type surfactant" may be used interchangeably with the "sulfonate-type anionic surfactant".
In some embodiments, the anionic surfactant of the present invention is a phosphate surfactant.
In particular embodiments, the phosphate surfactant may have a structure represented by formula I or formula II:
R(OC 2 H 4 ) n OPO(OM) 2 (I)
(R(OC 2 H 4 ) n ) 2 OPO(OM) (II)
wherein n=any integer from 0 to 10; m is a K+, na+, diethanolamine residue, or triethanolamine residue; when n is 0, R is C8-C18 alkyl; when n is not 0, R is alkyl or alkylphenyl.
Specifically, examples of suitable C8-C18 alkyl groups are various isomeric octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl and octadecyl groups.
Examples of suitable alkyl groups in the context of the present invention are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, tert-pentyl, neopentyl and the various isomeric hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl and octadecyl groups.
In an exemplary embodiment, the phosphate surfactant is a phenolic ether phosphate or a dodecyl phosphate; for example potassium phenolether phosphate or sodium dodecyl phosphate.
In some embodiments, the anionic surfactant of the present invention is a sulfonate-based surfactant.
In an exemplary embodiment, the sulfonate surfactant is selected from aryl sulfonate surfactants. An example of an aryl sulfonate surfactant is a benzenesulfonate surfactant, for example, an alkylbenzenesulfonic surfactant.
In another exemplary embodiment, the sulfonate surfactant is selected from amide sulfonate surfactants. An example of an amidosulfonate surfactant is an acyl taurate surfactant, e.g., an alkyl fatty acyl taurate surfactant.
In the second agent of the invention, the concentration of the anionic surfactant may be from 0.25 to 30g/L, in particular from 0.5 to 20g/L. For example, about 0.3g/L, about 0.4g/L, about 0.5g/L, about 1g/L, about 2g/L, about 3g/L, about 4g/L, about 5g/L, about 10g/L, about 15g/L, about 20g/L, about 25g/L, or about 30g/L.
In some embodiments, a suitable buffer may be included in the second reagent that may be used to provide a suitable storage environment for the components in the reagent.
The kind of the buffer is not particularly limited, and any buffer known in the art that can be used to provide a suitable environment for nitrotetrazolium blue can be used. Such buffers may be, for example, phosphate buffer, MES buffer, MOPS buffer, MOPSO buffer, HEPES buffer and Tris buffer. Also, the pH and ionic strength of the buffer are not particularly limited, and may be determined according to the kind of the buffer selected, and the pH may be, for example, 6.0 to 9.0; the ionic strength may be 100-500mmol/L.
In the present invention, the concentration of nitrotetrazolium blue is not particularly limited, and a concentration used in a conventional nitrotetrazolium blue method may be employed, and such a concentration may be, for example, 0.1 to 10mmol/L.
Those skilled in the art will appreciate that the addition of carbonate buffer is intended to provide a suitable reaction environment during the detection of fructosamine using nitrotetrazolium blue. Thus, the person skilled in the art is able to select a suitable use range for the carbonate buffer, for example the pH may be 7.0-11.0 and the ionic strength may be 100-800mmol/L.
In some embodiments, each of the agents of the present invention may also contain a preservative. In the present invention, a preservative means an agent for extending the shelf life of the labeled microparticles.
The type of the preservative is not particularly limited, and any of the usual preservatives commonly found in the field of diagnostic agents can be used. Exemplary preservatives may be selected from one or more of sodium azide, phenol, parahydroxybenzoic acid, benzoic acid, sodium benzoate, sorbic acid, potassium sorbate, calcium propionate, xylenol, nipagin ester, permanganate, antibiotics (such as gentamycin, dichloroacetamide, proClin series, available from SUPELCO corporation, etc.), ethyl parahydroxybenzoate, and sodium ethyl mercuric thiosulfate.
In addition, the kit of the invention may also include a calibrator.
The kit of the invention is a kit based on a Nitrotetrazolium Blue (NBT) method.
In another aspect, the invention provides a method of detecting fructosamine, comprising:
adding a sample, a first reagent and a second reagent, and uniformly mixing;
after a certain time of reaction, measuring absorbance; and
calculating fructosamine concentration according to the measured absorbance,
wherein the first reagent comprises a carbonate buffer; the second reagent contains nitrotetrazolium blue and an anionic surfactant of the present invention.
In particular embodiments, the sample is derived from a human or mammal (e.g., pig, cow, goat, sheep, dog, and cat), preferably from a human.
In the present invention, a kit or method detects a serum or plasma sample from a subject. In particular, the plasma sample may be heparin plasma or EDTA plasma.
In one exemplary embodiment, the sample and the first reagent are first added and mixed; after about two minutes, adding a second reagent to react for about 6-10 minutes, and then measuring absorbance; and calculating the levan content according to the measured absorbance.
In another exemplary embodiment, the sample and the second reagent are first added and mixed; after about two minutes, the first reagent is added to react for about 6-10 minutes, and then the absorbance is measured; and calculating the levan content according to the measured absorbance.
In yet another exemplary embodiment, the sample, the first reagent, and the second reagent are added and mixed well; then reacting for about 8-12 minutes, and then measuring absorbance; and calculating the levan content according to the measured absorbance.
The present invention may include steps other than those specifically mentioned. In particular, the step of providing the sample may be included before adding the sample. Furthermore, some or all of the steps of the present invention may be aided by automated equipment.
The reaction temperature of the detection method of the present invention is at a temperature suitable for the reaction of nitrotetrazolium blue with fructosamine, and such a temperature may be, for example, 37 ℃.
In a further aspect, there is provided the use of the first and second reagents of the invention in the preparation of a kit for the detection of fructosamine.
In yet another aspect, the present invention provides the use of phosphate-based anionic surfactants and sulfonate-based anionic surfactants in improving the consistency of fructosamine detection results for serum samples and plasma samples.
In a specific embodiment, the phosphate type anionic surfactant and the sulfonate type anionic surfactant are present in the same reagent as the nitrotetrazolium blue.
By adding the phosphate anionic surfactant and the sulfonate anionic surfactant, the invention obtains good-consistency detection results when detecting serum, heparin plasma and EDTA plasma, and meanwhile, the detection performance of the reagent is not affected. Accordingly, the fructosamine detection reagent has the advantages of wide application range and improved operation convenience.
Detailed Description
The advantages and various effects of the present invention will be more clearly apparent from the following detailed description and examples. It will be understood by those skilled in the art that these specific embodiments and examples are intended to illustrate the invention, not to limit the invention.
Example 1
The fructosamine detection reagent of the present invention is formulated according to the following table 1, wherein reagent 1 and reagent 2 are liquid components independent of each other.
TABLE 1
| Reagent 1: | reagent 2: |
| carbonate buffer 100mmol/L (pH 7.0) | Phosphate buffer 100mmol/L (pH 6.0) |
| Nitrotetrazolium blue 0.1mmol/L | |
| 0.5g/L potassium phenolether phosphate | |
| The solvent is purified water | The solvent is purified water |
Example 2
The fructosamine detection reagent of the present invention is formulated according to the following table 2, wherein reagent 1 and reagent 2 are liquid components independent of each other.
TABLE 2
| Reagent 1: | reagent 2: |
| carbonate buffer 400mmol/L (pH 9.0) | Phosphate buffer 250mmol/L (pH 7.5) |
| Nitrotetrazolium blue 5mmol/L | |
| 10g/L of phenolic ether phosphate potassium salt | |
| The solvent is purified water | The solvent is purified water |
Example 3
The fructosamine detection reagent of the present invention is formulated according to the following table 3, wherein reagent 1 and reagent 2 are liquid components independent of each other.
TABLE 3 Table 3
| Reagent 1: | reagent 2: |
| carbonate buffer 800mmol/L (pH 11.0) | Phosphate buffer 500mmol/L (pH 9.0) |
| Nitrotetrazolium blue 10mmol/L | |
| 20g/L of phenolic ether phosphate potassium salt | |
| The solvent is purified water | The solvent is purified water |
Example 4
The fructosamine detection reagent of the present invention is formulated according to the following table 4, wherein reagent 1 and reagent 2 are liquid components independent of each other.
TABLE 4 Table 4
EXAMPLE 5 fructosamine determination method
The test was performed with a fully automatic biochemical analyzer (mickey biochemical analyzer C800).
120 μl of reagent 2 was added to each of the sample (6 μl), blank tube (6 μl of purified water) and calibrator (6 μl) and mixed well, and the mixture was kept at 37℃for 2 minutes; zeroing a blank tube to measure absorbance A1;
120 μl of reagent 1 is added into the reaction solution obtained in the previous step, and the temperature is kept at 37 ℃ for 8 minutes; zeroing a blank tube to measure absorbance A2;
the fructosamine can reduce NBT to formazan under alkaline condition, and compared with fructosamine calibrator after the same treatment, and the fructosamine content in the sample is calculated according to absorbance change value.
Wherein:
ΔA U /min-sample absorbance rate of change;
ΔA C /min-the rate of change of absorbance of the calibrator;
C C concentration of fructosamine in the calibrator.
Example 6
Serum, EDTA plasma and heparin plasma samples collected from 15 subjects were tested using the reagents 1 and 2 prepared in examples 1 to 4, respectively, according to the measurement method in example 5, and the deviation ratio of heparin plasma/EDTA plasma to serum measurement results was calculated, and the results are shown in tables 5 to 8 below.
TABLE 5
TABLE 6
TABLE 7
TABLE 8
As can be seen from tables 4 to 8, the deviation of the detection results of the plasma samples from the serum samples was relatively low, and was controlled to be within 10%, even 7%, when the reagent combinations in examples 1 to 4 of the present invention were used. In other words, the kit of the present invention has good consistency in results when testing serum and plasma samples.
Comparative example 1
Fructosamine detection reagents were formulated without the anionic surfactant of the invention, wherein reagent 1 and reagent 2 are liquid components independent of each other, as shown in table 9 below.
TABLE 9
| Reagent 1: | reagent 2: |
| carbonate buffer 400mmol/L (pH 9.0) | Phosphate buffer 250mmol/L (pH 7.5) |
| Nitrotetrazolium blue 5mmol/L | |
| The solvent is purified water | The solvent is purified water |
Comparative example 2
Fructosamine detection reagents containing triton X-100 (a nonionic surfactant) were formulated according to the following table 10, wherein reagent 1 and reagent 2 were liquid components independent of each other.
Table 10
Comparative example 3
Fructosamine detection reagents containing polyoxyethylene stearyl ether (a nonionic surfactant) were formulated according to the following table 11, wherein reagent 1 and reagent 2 were liquid components independent of each other.
TABLE 11
| Reagent R1: | reagent R2: |
| carbonate buffer 400mmol/L (pH 9.0) | Phosphate buffer 250mmol/L (pH 7.5) |
| Nitrotetrazolium blue 5mmol/L | |
| 10g/L Polyoxyethylene stearyl ether | |
| The solvent is purified water | The solvent is purified water |
Example 7
Serum, EDTA plasma and heparin plasma samples collected from 15 subjects in example 6 were tested according to the assay method in example 5 using the reagents 1 and 2 prepared in comparative examples 1 to 3, and the deviation ratio of heparin plasma/EDTA plasma to serum detection was calculated, and the results are shown in tables 12 to 14 below.
Table 12
As can be seen from table 12, in the case where the anionic surfactant of the present invention was not added (i.e., the conventional fructosamine detection reagent based on the NBT method), the serum detection results were inferior to, and even more than 50% of, the plasma detection results.
TABLE 13
TABLE 14
As can be seen from tables 13 and 14, when the nonionic surfactant was added, the consistency of the serum test results and the plasma test results was poor, and the prepared reagent could not be used for testing the plasma sample.
Example 8
The fructosamine detection reagent of the present invention is formulated according to the following table 15, wherein reagent 1 and reagent 2 are liquid components independent of each other.
TABLE 15
| Reagent 1: | reagent 2: |
| carbonate buffer 400mmol/L (pH 9.0) | Phosphate buffer 250mmol/L (pH 7.5) |
| Nitrotetrazolium blue 5mmol/L | |
| Sodium dodecyl benzene sulfonate 10g/L | |
| The solvent is purified water | The solvent is purified water |
Example 9
The fructosamine detection reagent of the present invention is formulated according to the following table 16, wherein reagent 1 and reagent 2 are liquid components independent of each other.
Table 16
| Reagent 1: | reagent 2: |
| carbonate buffer 400mmol/L (pH 9.0) | Phosphate buffer 250mmol/L (pH 7.5) |
| Nitrotetrazolium blue 5mmol/L | |
| Sodium methyl lauroyl taurate 10g/L | |
| The solvent is purified water | The solvent is purified water |
Example 10
According to the measurement method in example 5, 5 pairs of serum and heparin plasma samples were tested using the reagent 1 and the reagent 2 prepared in examples 8 and 9, respectively, and the deviation ratio of heparin plasma to serum detection results was calculated, and the results are shown in table 17 below.
TABLE 17
As can be seen from table 17, the results were consistent well when serum and plasma samples were tested using the reagent combinations of examples 8 and 9 of the present invention.
Comparative example 4
Fructosamine detection reagents containing PD-104 (alkyl polyoxyethylene ether ammonium sulfate, a sulfate-type anionic surfactant) were formulated according to the following Table 18, wherein reagent 1 and reagent 2 were liquid components independent of each other.
TABLE 18
| Reagent R1: | reagent R2: |
| carbonate buffer 400mmol/L (pH 9.0) | Phosphate buffer 250mmol/L (pH 7.5) |
| Nitrotetrazolium blue 5mmol/L | |
| PD-104 10g/L | |
| The solvent is purified water | The solvent is purified water |
Comparative example 5
Fructosamine detection reagents containing sodium fatty acid polyoxyethylene ether sulfate (a sulfate-type anionic surfactant) were formulated according to the following table 19, wherein reagent 1 and reagent 2 were liquid components independent of each other.
TABLE 19
Comparative example 6
Fructosamine detection reagents containing 24P (a cationic surfactant) were formulated according to the following Table 20, wherein reagent 1 and reagent 2 were liquid components independent of each other.
Table 20
| Reagent R1: | reagent R2: |
| carbonate buffer 400mmol/L (pH 9.0) | Phosphate buffer 250mmol/L (pH 7.5) |
| Nitrotetrazolium blue 5mmol/L | |
| 24P 10g/L | |
| The solvent is purified water | The solvent is purified water |
Comparative example 7
Fructosamine detection reagents containing tween 20 (a nonionic surfactant) were formulated according to the following table 21, wherein reagent 1 and reagent 2 were liquid components independent of each other.
Table 21
| Reagent R1: | reagent R2: |
| carbonate buffer 400mmol/L (pH 9.0) | Phosphate buffer 250mmol/L (pH 7.5) |
| Nitrotetrazolium blue 5mmol/L | |
| Tween 20 10g/L | |
| The solvent is purified water | The solvent is purified water |
Comparative example 8
Fructosamine detection reagents containing 20AB (a zwitterionic surfactant) were formulated according to table 22 below, with reagent 1 and reagent 2 being liquid components independent of each other.
Table 22
Comparative example 9
A fructosamine detection reagent containing 20HD (a zwitterionic surfactant) was formulated according to Table 23 below, where reagent 1 and reagent 2 are liquid components independent of each other.
Table 23
| Reagent R1: | reagent R2: |
| carbonate buffer 400mmol/L (pH 9.0) | Phosphate buffer 250mmol/L (pH 7.5) |
| Nitrotetrazolium blue 5mmol/L | |
| 20HD 10g/L | |
| The solvent is purified water | The solvent is purified water |
Comparative example 10
The fructosamine detection reagent containing cationic alkyl polyglycoside was formulated according to the following table 24, wherein reagent 1 and reagent 2 are liquid components independent of each other.
Table 24
Example 11
Serum and heparin plasma samples collected from 5 subjects were tested using the reagents 1 and 2 prepared in comparative examples 4 to 10, respectively, according to the measurement method in example 5, and the deviation ratio of heparin plasma to serum measurement results was calculated, and the results are shown in table 25 below.
Table 25
As can be seen from table 25, when the sulfate-based anionic surfactant was added, the serum test results and the plasma test results were still greatly different, and the fructosamine level of the subject could not be detected by the plasma sample. In addition, when a nonionic, cationic or amphoteric surfactant is added, the serum detection result is poorly consistent with the plasma detection result.
Example 12
The fructosamine detection reagent of the present invention is formulated according to the following table 26, wherein reagent 1 and reagent 2 are liquid components independent of each other.
Table 26
Example 13
Serum and heparin plasma samples collected from 5 subjects in example 11 were tested according to the measurement method in example 5 using the reagent 1 and reagent 2 prepared in example 12, respectively, and the deviation ratio of heparin plasma to serum detection results was calculated, and the results are shown in table 27 below.
Table 27
/>
Claims (14)
1. A kit for detecting fructosamine in plasma comprising:
a first reagent comprising a carbonate buffer;
a second reagent comprising nitrotetrazolium blue, an anionic surfactant, and a buffer having a pH of 6.0-9.0; and
the calibration material is used for the calibration of the device,
wherein the anionic surfactant is phosphate anionic surfactant,
wherein the phosphate anionic surfactant has a structure shown in a formula I or a formula II,
R(OC 2 H 4 ) n OPO(OM) 2 (I)
(R(OC 2 H 4 ) n ) 2 OPO(OM)(II)
wherein n=any integer from 0 to 10; m is a K+, na+, diethanolamine residue, or triethanolamine residue; when n is 0, R is C8-C18 alkyl; when n is not 0, R is alkyl or alkylphenyl.
2. The kit of claim 1, wherein the anionic surfactant is selected from one or more of the following: phenolic ether phosphate and dodecyl phosphate.
3. The kit of claim 2, wherein the phenolic ether phosphate salt is a phenolic ether phosphate potassium salt.
4. The kit of claim 2, wherein the dodecyl phosphate salt is sodium dodecyl phosphate.
5. The kit of any one of claims 1 to 4, wherein the anionic surfactant is present in the second reagent at a concentration of 0.25-30g/L.
6. The kit of claim 5, wherein the anionic surfactant is present in the second reagent at a concentration of 0.5-20g/L.
7. A method for detecting fructosamine in blood plasma comprising:
adding a sample, a first reagent and a second reagent, and uniformly mixing;
after a certain time of reaction, measuring absorbance; and
calculating fructosamine concentration according to the measured absorbance,
wherein the first reagent comprises a carbonate buffer; the second reagent contains nitrotetrazolium blue, an anionic surfactant and a buffer solution with the pH value of 6.0-9.0,
wherein the anionic surfactant is phosphate anionic surfactant,
wherein the phosphate anionic surfactant has a structure shown in a formula I or a formula II,
R(OC 2 H 4 ) n OPO(OM) 2 (I)
(R(OC 2 H 4 ) n ) 2 OPO(OM)(II)
wherein n=any integer from 0 to 10; m is a K+, na+, diethanolamine residue, or triethanolamine residue; when n is 0, R is C8-C18 alkyl; when n is not 0, R is alkyl or alkylphenyl.
8. The method of claim 7, wherein the anionic surfactant is selected from one or more of the following: phenolic ether phosphate and dodecyl phosphate.
9. The method of claim 8, wherein the phenolic ether phosphate salt is a phenolic ether phosphate potassium salt.
10. The method of claim 8, wherein the dodecyl phosphate salt is sodium dodecyl phosphate.
11. The method of claim 7, wherein the concentration of the anionic surfactant in the second reagent is 0.25-30g/L.
12. The method of claim 11, wherein the concentration of the anionic surfactant in the second reagent is 0.5-20g/L.
13. The method of any one of claims 7 to 12, wherein the sample is heparin plasma or EDTA plasma.
14. Use of a second reagent comprising an anionic surfactant as defined in any one of claims 1 to 6 for improving the consistency of fructosamine detection results for serum samples and plasma samples.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011345976.4A CN112326639B (en) | 2020-11-25 | 2020-11-25 | Kit and method for detecting fructosamine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011345976.4A CN112326639B (en) | 2020-11-25 | 2020-11-25 | Kit and method for detecting fructosamine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112326639A CN112326639A (en) | 2021-02-05 |
| CN112326639B true CN112326639B (en) | 2024-01-05 |
Family
ID=74308737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011345976.4A Active CN112326639B (en) | 2020-11-25 | 2020-11-25 | Kit and method for detecting fructosamine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112326639B (en) |
Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK314987D0 (en) * | 1986-06-21 | 1987-06-19 | Boehringer Mannheim Gmbh | PROCEDURE FOR SPECIFIC DETERMINATION OF SERUM FRUCTOSAMINE CONTENT AND ITS SUITABLE REAGENT MIXTURE |
| JPH02251766A (en) * | 1989-03-24 | 1990-10-09 | Sanko Junyaku Kk | Measuring method of fructosamine |
| EP0971037A2 (en) * | 1998-07-06 | 2000-01-12 | Kirkegaard & Perry Laboratories, Inc. | Stable reagent for formazan-based assay |
| JP2001190299A (en) * | 1999-11-01 | 2001-07-17 | Asahi Kasei Corp | Method for examining preliminary group of diabetes mellitus |
| WO2005049858A1 (en) * | 2003-11-19 | 2005-06-02 | Daiichi Pure Chemicals Co., Ltd. | Method of determining substrate contained in hemoglobin-containing sample |
| TW200638040A (en) * | 2005-04-19 | 2006-11-01 | Eps Bio Technology Corp | Fructosamine reagent |
| WO2007072941A1 (en) * | 2005-12-22 | 2007-06-28 | Kyowa Medex Co., Ltd. | Method for determination of glycosylated protein |
| CN103808712A (en) * | 2012-11-05 | 2014-05-21 | 深圳迈瑞生物医疗电子股份有限公司 | Liquid reagent kit applied to acid phosphatase detection and detection method |
| CN105223192A (en) * | 2015-09-14 | 2016-01-06 | 广州金域医学检验中心有限公司 | A kind of glycated serum protein detects reagent and application thereof |
| CN105241830A (en) * | 2015-09-23 | 2016-01-13 | 广州金域医学检验中心有限公司 | Glycolated serum albumin detection reagent and application thereof |
| CN107367507A (en) * | 2016-04-25 | 2017-11-21 | 爱科来株式会社 | Analysis method, analytical reagent, assay kit and the analysis test film of glycated proteins |
| CN109239059A (en) * | 2018-08-30 | 2019-01-18 | 中拓生物有限公司 | A kind of glycated serum protein assay kit and its preparation method and application |
| CN111315388A (en) * | 2017-11-03 | 2020-06-19 | 卡莱多生物科技有限公司 | Glycan formulations and methods of use for hyperammonemia |
| CN111919118A (en) * | 2018-04-13 | 2020-11-10 | 豪夫迈·罗氏有限公司 | Methods and compositions for detecting and analyzing analytes |
| CN111965365A (en) * | 2020-07-23 | 2020-11-20 | 武汉生之源生物科技股份有限公司 | Fructosamine assay kit |
| CN112067562A (en) * | 2020-08-03 | 2020-12-11 | 海丰生物科技（北京）有限公司 | Calibration product for fructosamine detection and detection kit using same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020182600A1 (en) * | 2001-04-11 | 2002-12-05 | Smith Jack V. | Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques |
| US6900058B2 (en) * | 2003-03-11 | 2005-05-31 | Bionostics, Inc. | Control solution for photometric analysis |
-
2020
- 2020-11-25 CN CN202011345976.4A patent/CN112326639B/en active Active
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK314987D0 (en) * | 1986-06-21 | 1987-06-19 | Boehringer Mannheim Gmbh | PROCEDURE FOR SPECIFIC DETERMINATION OF SERUM FRUCTOSAMINE CONTENT AND ITS SUITABLE REAGENT MIXTURE |
| JPH02251766A (en) * | 1989-03-24 | 1990-10-09 | Sanko Junyaku Kk | Measuring method of fructosamine |
| EP0971037A2 (en) * | 1998-07-06 | 2000-01-12 | Kirkegaard & Perry Laboratories, Inc. | Stable reagent for formazan-based assay |
| JP2001190299A (en) * | 1999-11-01 | 2001-07-17 | Asahi Kasei Corp | Method for examining preliminary group of diabetes mellitus |
| WO2005049858A1 (en) * | 2003-11-19 | 2005-06-02 | Daiichi Pure Chemicals Co., Ltd. | Method of determining substrate contained in hemoglobin-containing sample |
| CN1882696A (en) * | 2003-11-19 | 2006-12-20 | 第一化学药品株式会社 | Method of determining substrate contained in hemoglobin-containing sample |
| TW200638040A (en) * | 2005-04-19 | 2006-11-01 | Eps Bio Technology Corp | Fructosamine reagent |
| WO2007072941A1 (en) * | 2005-12-22 | 2007-06-28 | Kyowa Medex Co., Ltd. | Method for determination of glycosylated protein |
| CN103808712A (en) * | 2012-11-05 | 2014-05-21 | 深圳迈瑞生物医疗电子股份有限公司 | Liquid reagent kit applied to acid phosphatase detection and detection method |
| CN105223192A (en) * | 2015-09-14 | 2016-01-06 | 广州金域医学检验中心有限公司 | A kind of glycated serum protein detects reagent and application thereof |
| CN105241830A (en) * | 2015-09-23 | 2016-01-13 | 广州金域医学检验中心有限公司 | Glycolated serum albumin detection reagent and application thereof |
| CN107367507A (en) * | 2016-04-25 | 2017-11-21 | 爱科来株式会社 | Analysis method, analytical reagent, assay kit and the analysis test film of glycated proteins |
| CN111315388A (en) * | 2017-11-03 | 2020-06-19 | 卡莱多生物科技有限公司 | Glycan formulations and methods of use for hyperammonemia |
| CN111919118A (en) * | 2018-04-13 | 2020-11-10 | 豪夫迈·罗氏有限公司 | Methods and compositions for detecting and analyzing analytes |
| CN109239059A (en) * | 2018-08-30 | 2019-01-18 | 中拓生物有限公司 | A kind of glycated serum protein assay kit and its preparation method and application |
| CN111965365A (en) * | 2020-07-23 | 2020-11-20 | 武汉生之源生物科技股份有限公司 | Fructosamine assay kit |
| CN112067562A (en) * | 2020-08-03 | 2020-12-11 | 海丰生物科技（北京）有限公司 | Calibration product for fructosamine detection and detection kit using same |
Non-Patent Citations (4)
| Title |
|---|
| Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control;Johnson R N，等;Clinica chimica acta;第127卷(第1期);87-95 * |
| 史岸冰.代谢与疾病基础研究实验技术.华中科技大学出版社,2019,(第1版),43-46. * |
| 小剂量联麦氧钒对糖尿病大鼠肝脏及机体氧化应激影响的研究;潘云;中国优秀硕士学位论文电子期刊医药卫生科技(第01期);1-63 * |
| 海参磷脂型二十碳五烯酸降血糖作用及机制的研究;徐雷雷;中国优秀硕士学位论文电子期刊医药卫生科技(第03期);1-113 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112326639A (en) | 2021-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107449748B (en) | High-density lipoprotein cholesterol detection kit and use method thereof | |
| Deeg et al. | Kinetic enzymic method for automated determination of total cholesterol in serum. | |
| CN109239059B (en) | Glycated serum protein assay kit and preparation method and application thereof | |
| CN106383116A (en) | Kit for detecting high density lipoprotein cholesterol | |
| CN107505272B (en) | Low-density lipoprotein cholesterol detection kit and use method thereof | |
| EP0218127B1 (en) | Method and reagent for the specific determination of hdl-cholesterol in serum | |
| EP0432642B1 (en) | Reagent composition, methods and kits for quantification of magnesium or calcium and magnesium | |
| US3595755A (en) | Detection of hydrogen peroxide | |
| EP1693462A1 (en) | Method of determining substrate contained in hemoglobin-containing sample | |
| US4366244A (en) | Method for measuring serum cholesterol | |
| CN108287245B (en) | Kit for measuring glycosylated hemoglobin and preparation method thereof | |
| EP4029948A1 (en) | Method and kit for quantifying small, dense ldl cholesterol | |
| EP0387784A2 (en) | Quantitative determination of bilirubin and a reagent therefor | |
| CN111944872A (en) | Reagent combination, reagent or kit for measuring creatinine content | |
| CN110988358A (en) | High-sensitivity human urine α 2-macroglobulin detection kit | |
| CN112326639B (en) | Kit and method for detecting fructosamine | |
| Bergman et al. | Effect of detergent on kinetic Jaffé-method assay of creatinine. | |
| Sisman et al. | Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Marker of Diabetic Nephropathy in Type 1 Diabetic Patients. | |
| EP0253548A2 (en) | Method for the determination of occult blood and chemical compositions therefor | |
| US6991913B1 (en) | Procedure for the determination of triglyceride contained in low density lipoprotein | |
| CN104673878B (en) | Kit for measuring concentration ratio of glycated albumin and albumin by virtue of single system | |
| US6114134A (en) | Method for assaying biological specimens for substances contained in the components thereof and reagent to be used in this method | |
| KR20010108370A (en) | Method for quantitating cholesterol | |
| CN110736846A (en) | Reagent, method and kit for measuring small and dense lipoproteins | |
| CN110791549B (en) | Method and kit for quantitatively determining small dense low density lipoprotein cholesterol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |